BioSpace News Archive

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into material definitive agreements to sell its liquid drug manufacturing facility in Carmel, NY.

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage gamma-delta T cell therapies biopharmaceutical company, today announced March conference presentations.

Eyenovia, Inc. today announced that the company has entered into a Securities Purchase Agreement with Armistice Capital Master Fund Ltd.

dentalcorp Holdings Ltd. announced today that it will release its fourth quarter and full year 2021 financial results before market open on Friday, March 25, 2022.

AccuStem Sciences, Inc. today announced the formation of its executive leadership team as the first major step toward commercializing new products in the oncology space.

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations, including one oral and three poster presentations, highlighting data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming American Academy of Neurology (AAN) annual meeting, being held April 2 – 7, 2022, in Seattle, Washington.

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today it will present at the 42nd Annual Cowen Health Care Conference to be held virtually March 7 – 9, 2022.

Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people affected by epilepsies and rare neurological disorders, today announced that management will participate virtually in the “Orphan Neuro and Neuromuscular” panel discussion at the Cowen 42nd Annual Health Care Conference.

Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, announced that new data from the company’s research and development program for FINTEPLA® (fenfluramine) in Lennox Gastaut syndrome (LGS) will be presented at the hybrid American Academy of Neurology (AAN) Annual Meeting 2022.

The All of Us Research Program’s Journey mobile exhibit is traveling across the country to engage communities that have been historically underrepresented in medical research.